About Tim Knotnerus | CEO, AgomAb Therapeutics

Tim is CEO and member of the Board of Directors of Agomab Therapeutics, a Belgian biotech company focusing on growth factor biology and developing therapeutics for fibrotic indications. Together with the team, he has raised $240 million and developed a broad pipeline since joining Agomab in 2019. Prior to Agomab, Tim held the position of VP Corporate Development at AM-Pharma where he and the team executed a Phase IIb trial in patients with acute kidney injury, secured a $600M option-to-buy deal with Pfizer and raised significant private financing rounds. Prior to that, Tim was a Senior Associate at Aescap Venture, a VC fund investing in European medical companies. Tim received the CEO of the year award by European Lifestars, was selected as an Endpoints 20 under 40 and In Vivo rising leader and is a Termeer Fellow. He holds an executive MBA from IMD, where he was named Valedictorian, and earned two Master degree programs from Utrecht University.

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.